Financial Statements March 31, 2023



Independent auditor's report

To the Board of Directors of Sinai Health System

Our opinion

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Sinai Health System (the Hospital) as at March 31, 2023 and the results of its operations, its remeasurement gains and losses and its cash flows for the year then ended in accordance with Canadian public sector accounting standards.

What we have audited

The Hospital's financial statements comprise:

- the statement of financial position as at March 31, 2023;
- the statement of operations and changes in net deficit for the year then ended;
- the statement of remeasurement gains (losses) for the year then ended;
- the statement of cash flows for the year then ended; and
- the notes to the financial statements, which include significant accounting policies and other explanatory information.

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Hospital in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian public sector accounting standards, and for such internal control as

PricewaterhouseCoopers LLP PwC Tower, 18 York Street, Suite 2500, Toronto, Ontario, Canada M5J 0B2 T: +1 416 863 1133, F: +1 416 365 8215, ca_toronto_18_york_fax@pwc.com



management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Hospital's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Hospital or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Hospital's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting
 a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
 involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Hospital's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Hospital's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Hospital to cease to continue as a going concern.



• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Pricewaterhouse Coopers LLP

Chartered Professional Accountants, Licensed Public Accountants

Toronto, Ontario June 29, 2023

Statement of Financial Position

As at March 31, 2023

(in thousands of dollars)

	2023 \$	2022 \$ (note 2)
Assets		
Current assets Cash Short-term investments Restricted cash and investments (note 4) Accounts receivable (note 5) Redevelopment receivable (note 6) Due from related entities (note 13) Inventories Prepaid deposits and sundry assets	132,932 148,752 12,798 52,189 92,189 92,189 15,474 5,469 7,027	291,997 147,934 14,036 61,194 - 16,880 3,798 7,998
	466,830	543,837
Restricted cash and investments (note 4)	197,682	33,630
Other long-term assets	8,997	8,199
Long-term redevelopment receivable (note 6)	19,987	75,441
Due from related entities (note 13)	8,467	9,265
Capital and intangible assets (note 7)	1,401,717	1,360,864
	2,103,680	2,031,236
Liabilities		
Current liabilities Accounts payable and accrued liabilities Due to related entities (note 13) Administered funds Current portion of long-term debt (note 8) Current portion of long-term redevelopment obligation (note 10) Current portion of deferred contributions (note 12)	250,026 545 12,798 2,139 135,813 108,532	235,049 1,083 14,036 2,047 9,097 102,725
	509,853	364,037
Other long-term liabilities (note 9)	27,082	25,360
Long-term debt (note 8)	421,149	424,125
Long-term redevelopment obligation (note 10)	310,522	401,975
Employee future benefits (note 11)	31,961	32,156
Deferred contributions (note 12)	814,209	787,527
	2,114,776	2,035,180
Net deficit consists of Unrestricted and invested in capital assets Accumulated remeasurement gains (losses)	(11,657) 561	(3,554) (390)
	(11,096)	(3,944)
	2,103,680	2,031,236

Commitments and contingencies (note 15)

Approved by the Board

_____ Director _

Director

Sinai Health System Statement of Operations and Changes in Net Deficit **For the year ended March 31, 2023**

(in thousands of dollars)

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		2023 \$	2022 \$
Salaries and wages410,150391,928Employee benefits95,62292,176General supplies and other157,240174,334Medical and surgical supplies27,01925,708Drugs14,40413,615Amortization of equipment24,63721,999Interest740,085731,534Excess of income over expenses before the undernoted3,55119,883Amortization of deferred capital contributions39,05340,685Amortization of building and research equipment(49,158)(50,759) 	Ministry of Health (MOH) COVID-19 funding (note 3) Patient revenue Preferred accommodation Research funding Commercial Other revenue and recoveries	37,675 14,316 8,250 79,530 10,738 60,007 5,448	71,527 13,374 8,236 72,491 8,768 71,339 5,907
Amortization of deferred capital contributions39,05340,685Amortization of building and research equipment(49,158)(50,759)(10,105)(10,074)MOH funding – interest on building19,99119,647Interest cost on building (MOH share)(19,991)(19,647)(Deficiency) Excess of income over expenses for the year(6,554)9,809Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-	Salaries and wages Employee benefits General supplies and other Medical and surgical supplies Drugs Amortization of equipment	95,622 157,240 27,019 14,404 24,637 11,013	92,176 174,334 25,708 13,615 21,999 11,774
Amortization of building and research equipment(49,158)(50,759)(10,105)(10,074)MOH funding – interest on building19,99119,647Interest cost on building (MOH share)(19,991)(19,647)(Deficiency) Excess of income over expenses for the year(6,554)9,809Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)	Excess of income over expenses before the undernoted	3,551	19,883
MOH funding – interest on building(10,105)(10,074)Interest cost on building (MOH share)(19,991)19,647(19,991)(19,647)-(Deficiency) Excess of income over expenses for the year(6,554)9,809Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-	Amortization of deferred capital contributions	39,053	40,685
MOH funding – interest on building19,99119,647Interest cost on building (MOH share)(19,991)(19,647)(Deficiency) Excess of income over expenses for the year(6,554)9,809Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-	Amortization of building and research equipment	(49,158)	(50,759)
Interest cost on building (MOH share)(19,991)(19,647)(Deficiency) Excess of income over expenses for the year(6,554)9,809Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-		(10,105)	(10,074)
(Deficiency) Excess of income over expenses for the year(6,554)9,809Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-	MOH funding – interest on building	19,991	19,647
Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-	Interest cost on building (MOH share)	(19,991)	(19,647)
Net deficit – Beginning of year(3,554)(13,363)Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2)(1,549)-			-
Adjustment for asset retirement obligation to net deficit – Beginning of year (note 2) (1,549) -	(Deficiency) Excess of income over expenses for the year	(6,554)	9,809
Beginning of year (note 2) (1,549) -	Net deficit – Beginning of year	(3,554)	(13,363)
Net deficit – End of year (11,657) (3,554)		(1,549)	-
	Net deficit – End of year	(11,657)	(3,554)

Statement of Remeasurement Gains (Losses) For the year ended March 31, 2023

(in thousands of dollars)

	2023 \$	2022 \$
Accumulated remeasurement losses – Beginning of year	(390)	(1,968)
Unrealized gain attributable to interest rate swap (note 8(e))	951	1,578
Accumulated remeasurement gains (losses) – End of year	561	(390)

Statement of Cash Flows For the year ended March 31, 2023

(in thousands of dollars)

	2023 \$	2022 \$ (note 17)
Cash provided by (used in)		
Operating activities (Deficiency) excess of income over expenses for the year Items not affecting cash Amortization of equipment Amortization of building and research equipment Amortization of deferred capital contributions (note 12) Recognition of deferred designated and research contributions (note 12) Allowance for potentially uncollectible amounts Employee future benefits (note 11) Net liabilities assumed on distribution from Trusts (note 13) Loss on disposal of capital assets Equity income from government business enterprises Decrease (increase) in due from related entities	(6,554) 24,637 49,158 (27,056) (73,718) 251 1,497 - 118 (1,309) 2,204	9,809 21,999 50,759 (45,387) (77,109) (201) 1,902 1,974 44 (2,572) (2,998)
Decrease in due to related entities Deferred contributions received Payment for employee future benefits Increase in other long-term assets Increase in other long-term liabilities	(538) 79,525 (1,692) (798) 	(7) 82,986 (1,667) (893) 2,545
Net change in non-cash working capital (note 14(a))	47,207 21,793 69,000	41,184 71,818 113,002
Financing activities Repayment of long-term debt Proceeds from long-term debt Repayment of long-term redevelopment obligation Deferred capital contributions received (note 12) Receipts from long-term redevelopment receivables Decrease in restricted cash	(1,014) 25 (9,097) 17,003 718 7,635	2,959 24 (92,730) 32,293 101,845 1,121 45,512
Investing activities Cash acquired on distribution from Trusts (note 13) Proceeds from sale of investments Purchase of investments	506,000 (670,350) (164,350)	3,914 - - 3,914
Capital activities Purchase of capital and intangible assets	(71,350)	(84,509)
(Decrease) increase in cash during the year	(159,065)	77,919
Cash – Beginning of year	291,997	214,078
Cash – End of year	132,932	291,997

Non-cash transactions (note 14(b))

1 Organization

Sinai Health System (the Hospital) is a public teaching and research hospital affiliated with the University of Toronto. The Hospital provides patient care, teaches healthcare professionals, conducts research and provides chronic care and rehabilitation services.

The Hospital is a registered charity under the Income Tax Act (Canada) and accordingly is exempt from income taxes, provided certain requirements of the Income Tax Act (Canada) are met.

The Hospital is funded primarily by the Province of Ontario in accordance with budget arrangements established by both the Ministry of Health (MOH or the Ministry) and Ontario Health (OH).

2 Summary of significant accounting policies

Basis of presentation

These financial statements have been prepared by management in accordance with Canadian public sector accounting standards (PSAS), including standards that apply to government not-for-profit organizations. A summary of the significant accounting policies is as follows.

Revenue recognition

The Hospital follows the deferral method of accounting for contributions, which includes donations and government grants. Unrestricted contributions are recognized as revenue when received or receivable. Externally restricted contributions are recognized as revenue in the year in which the related expenses or activity are incurred.

Under the Health Insurance Act (Ontario) and the regulations thereunder, the Hospital is funded primarily by the Province of Ontario in accordance with funding arrangements established by the MOH and OH.

Operating grants are recorded as revenue in the period to which they relate. Grants approved but not received at the end of a period are accrued. Where a portion of a grant relates to a future period, it is deferred and recognized in a subsequent period. These financial statements reflect management's best estimates of funding arrangements with the MOH and OH.

All investment income is unrestricted and recognized as revenue when earned.

Amortization of building and research equipment is not included in the financial measures that are defined as part of the Hospital Service Accountability Agreement (HSAA) and accordingly has been reflected as an undernoted item in the statement of operations and changes in net deficit with the corresponding realization of revenue for deferred contributions and grants.

Contributions received in the form of donations and grants for specific capital expenditures are initially deferred and recorded as deferred capital contributions. These deferred contributions are realized into revenue on the same basis as the amortization of the cost of the related capital and intangible assets. Funding for capital expenditures is recorded when there is an agreement with the ultimate donor and there is reasonable assurance the funding will be received in the near future.

Revenue generated from patient, preferred accommodation and commercial activities is recognized when the goods are sold or the service is provided, the amounts can be reasonably estimated and collection is reasonably assured.

Other revenue and recoveries are primarily derived from various service level agreements with other institutions and are recognized when the goods are sold or the service is provided, the amounts can be reasonably estimated and collection is reasonably assured.

Cash, Investments and Restricted cash

Cash includes operating funds and cash held for research, capital and other designated purposes.

As at March 31, 2023, all cash was held by Canadian schedule 1 banks. In 2023, the Hospital adopted a new accounting policy whereby internally restricted cash and investments held for the purpose of future capital investment is classified as a non-current asset. This change in policy was applied retroactively to April 1, 2021. As a result, \$27,066 was reclassified from Short-term investments to Restricted cash and investments as at March 31, 2022. Cash is classified as a current asset, unless it is externally restricted or internally restricted for future capital investment, in which case it is classified as a non-current asset.

Investments include guaranteed investment certificates (GICs) with a major financial institution. The GICs are redeemable at any time, maturing between July 31, 2023 and January 30, 2024 (2022 – April 29, 2024). The interest on the GICs ranges from 5.30% to 6.04% (2022 – 0.75% to 2.00%) based on the length of the period held. Investments are recorded at amortized cost.

Inventories

Inventories consist primarily of hospital supplies held for patient care and are recorded at the lower of cost and replacement cost. Cost is determined by the first-in, first-out method.

Capital and intangible assets

Capital and intangible assets are stated at cost, less accumulated amortization. Assets acquired under capital leases are amortized over the estimated lives of the assets or over the lease term, as appropriate.

Intangible assets are identifiable non-monetary assets without physical substance. Intangible assets acquired are initially recorded at cost and are amortized over their expected useful lives, unless the life is determined to be indefinite, in which case no amortization expense is recognized.

March 31, 2023

(in thousands of dollars)

Contributed capital and intangible assets are recorded at fair value at the date of contribution. When capital and intangible assets no longer contribute to the Hospital's ability to provide services, their carrying amounts are written down to their residual value. Costs incurred for new facilities, or that substantially increase the useful lives of existing capital and intangible assets, are capitalized.

Capital and intangible assets are amortized on a straight-line basis over the estimated useful lives of the assets as follows:

Land	not amortized
Artwork	not amortized
Building	7 to 40 years
Equipment	3 to 20 years
Software	3 to 5 years
Equipment under capital lease	3 to 20 years
Customer relationships	20 years
Lease agreement	7.5 years
Construction-in-progress	not amortized

Construction-in-progress comprises direct construction, development costs and capitalized interest. Interest costs, net of related interest income, are capitalized during the construction period. No amortization is recorded until construction is substantially complete and the assets are put in use.

Impairment of long-lived assets

An impairment charge is recorded for long-lived assets when a capital asset no longer has any long-term service potential. The impairment loss is calculated as the difference between the net carrying value of the asset over any residual value.

Contributed services

Certain ancillary services of the Hospital are voluntarily provided by the community. Since these services are not normally purchased by the Hospital and because of the difficulties in determining their fair value, these contributed services are not recognized in these financial statements.

Administered funds

Certain funds are administered by the Hospital on behalf of clinical groups. Transactions in the funds are not Hospital operating activities and do not flow through the statement of operations and changes in net deficit. Since these funds are held under administration, they are recorded as restricted cash on the statement of financial position with a corresponding liability.

Employee future benefit plans

• Pension

Employees of the Hospital are eligible to be members of the Healthcare of Ontario Pension Plan (HOOPP or the Plan), which is a multi-employer, defined benefit pension plan. Contributions made to HOOPP are expensed as funded, as the Plan is accounted for as a defined contribution plan.

• Other than pension

Employees are also entitled to certain other non-pension, post-employment benefits. The Hospital accrues its obligations under non-pension employee benefit plans as employees render services and has adopted the following policies:

- The cost of non-pension post-employment benefits earned by employees is determined by an actuary using the projected benefit method pro-rated on length of service and management estimated assumptions with regard to retirement age of employees and expected healthcare costs.
- The accrued benefit obligation related to employee benefits is discounted using current interest rates based on the Hospital's cost of borrowing.
- Past service costs arising from plan amendments are expensed when incurred.
- Actuarial gains and losses on the accrued benefit obligation arise from changes in the actuarial assumptions used to determine the accrued benefit obligations. The net accumulated actuarial gains or losses are amortized over the average remaining service period of active employees.

Related entities

Investments in Mount Sinai Fertility Corp., Mount Sinai Services Inc. and 2234998 Ontario Inc. have been determined to be Government Business Enterprises and therefore are accounted for using the modified equity method. Income is recorded in other revenue and recoveries in the statement of operations and changes in net deficit. The investments are initially recorded at cost and adjusted thereafter to recognize the Hospital's share of the entity's net surplus or deficit. Any distributions received are accounted for using the modified equity method. The Centre for Phenogenomics is a joint venture and is accounted for using the modified equity method. All other related entities and transactions described in note 13 are disclosed.

Financial instruments

The Hospital's financial assets consist of cash, short-term investments, restricted cash, accounts receivable, redevelopment receivable and due from related entities, and financial liabilities consist of accounts payable and accrued liabilities, due to related entities, administered funds, long-term debt, long-term redevelopment obligation and interest rate swap.

Financial instruments, except for long-term debt, are initially recorded at fair value. Long-term debt is initially recorded at cost. The Hospital's financial instruments are subsequently measured as follows:

Assets/liabilities	Measurement category
Cash	amortized cost
Short-term investments	amortized cost
Restricted cash	amortized cost
Accounts receivable	amortized cost
Redevelopment receivable	amortized cost
Due from related entities	amortized cost
Accounts payable and accrued liabilities	amortized cost
Due to related parties	amortized cost
Administered funds	amortized cost
Long-term debt	amortized cost
Long-term redevelopment obligation	amortized cost
Interest rate swap on long-term debt	fair value

For financial instruments measured using amortized cost, the effective interest rate method is used to determine interest income or expense.

Unrealized changes in fair value are recognized in the statement of remeasurement gains (losses) until they are realized, when they are transferred to the statement of operations and changes in net deficit. When a financial asset is sold, the unrealized gains and losses previously recognized in the statement of remeasurement gains (losses) are reversed and recognized in the statement of operations and changes in net deficit.

All financial assets, except interest rate swaps, are assessed for impairment on an annual basis. When a decline in value is determined to be other than temporary, the amount of the loss is reported in the statement of operations and changes in net deficit and any unrealized gain or loss is removed from the statement of remeasurement gains (losses).

Derivatives

Interest rate swap agreements are used as part of the Hospital's program to eliminate variability in future interest cash flows. Interest to be paid or received under such swap agreements is recognized as adjustments to interest expense.

Fair value measurement

PSAS requires the Hospital to classify fair value measurements using a fair value hierarchy, which includes three levels of information that may be used to measure fair value:

- Level 1 unadjusted quoted market prices in active markets;
- Level 2 observable or corroborated inputs, other than Level 1, such as quoted prices for similar assets or liabilities in inactive markets, or market data for substantially the full term of the assets or liabilities; and

• Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

Interest rate swaps are measured as Level 2 fair value instruments.

Measurement uncertainty

In preparing the financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.

A portion of the revenue recognized from the Ministry requires estimation. The Hospital has entered into accountability agreements that set out the rights and obligations of the parties in respect of funding provided to the Hospital by the Ministry for the year ended March 31, 2023. The accountability agreements set out certain performance standards and obligations that establish acceptable results for the Hospital's performance in a number of areas.

If the Hospital does not meet its performance standards or obligations as set out in the agreements or in specific funding letters, the Ministry has the right to adjust funding received by the Hospital. The Ministry is not required to communicate certain funding adjustments until after the submission of year-end data. Since this data is not submitted until after the completion of the financial statements, the amount of the Ministry funding received during a year may be increased or decreased subsequent to year-end. The amount of revenue recognized in these financial statements represents management's best estimates of amounts relating to funding that are reasonably assured of being received.

The coronavirus pandemic (COVID-19) has added to the Hospital's measurement uncertainty primarily due to judgment required by management to make significant assumptions related to critical estimates as they relate to funding received from the Ministry for incremental costs related to COVID-19. Calculating the amount of the incremental funding requires judgment in interpreting the related guidelines published by the Ministry as of the date of these financial statements. There is uncertainty as to the extent to which funding will be clawed back. While management believes the amounts recognized are reasonably assured of being received, there is a risk that funding provided may be clawed back and that COVID-19 funding has not been appropriately recorded in the statement of operations and changes in net deficit.

In November 2022, the Ontario Superior Court of Justice ruled that Bill 124 was unconstitutional, enabling unions to trigger reopener provisions in collective agreements. With the triggering of the reopener clause, the Hospital was required to resume negotiations with unions on compensation for the years that were previously capped by Bill 124. The Hospital has accrued its best estimate for retroactive wage increases due to the various union groups. There is uncertainty regarding this accrual as some contracts remain in negotiation or arbitration as at the date of these financial statements. While management believes the amounts recognized are reasonable estimates, there is a risk that actual payments will be higher or lower which could have a significant impact on the statement of operations and changes in net deficit.

Accounts requiring significant estimates include collectability of accounts receivable, accrued and contingent liabilities, deferred revenue and employee future benefits. Employee future benefits liabilities (note 11) are subject to measurement uncertainty because actual results may differ significantly from the Hospital's best long-term estimate of expected results. For example, the difference between actual results and actuarial assumptions regarding healthcare cost trend rates for retiree benefits may be significant. Actual results could differ from those estimates.

New accounting standards

In August 2018, the Public Sector Accounting Board (PSAB) issued PS 3280, Asset Retirement Obligations (PS 3280) to establish an accounting standard for public sector entities that addresses the accounting and reporting of legal obligations associated with the retirement of tangible capital assets. The new standard is effective for annual financial statements relating to fiscal years beginning on or after April 1, 2022, and earlier application is permitted. The Hospital has elected to adopt PS 3280 on a modified retroactive basis without restatement of prior period financial statements. As a result, Other long-term liabilities and Net deficit were increased by \$1,549 as of April 1, 2022.

Future accounting standards

In April 2021, the PSAB issued Section PS 3160, Public Private Partnerships (PS 3160). This new section establishes standards on how to account for public private partnership arrangements and is effective for years beginning on or after April 1, 2023. The Hospital is currently assessing the impact of this new standard.

In November 2018, PSAB issued Section PS 3400, Revenue (PS2400). This new section establishes standards on how to account for and report on revenue and is effective date deferred from April 1, 2022 to years beginning on/after April 1, 2023. The Hospital is currently assessing the impact of this new standard.

In November 2020, PSAB amended Section PS 1000, Financial Statement Concepts (PS 1000) and Section PS 1201, Financial Statement Presentation (PS 1201) and issued Public Sector Guideline 8, Purchased Intangibles (PSG-8). Section PS 1000 was amended to allow for recognition of purchased intangibles in financial statements. Section PS 1201 was amended to remove disclosure requirements for unrecognized purchased intangibles. PSG-8 explains the scope of the intangibles allowed to be recognized in financial statements given the removal of the recognition prohibition relating to purchased intangibles in Section PS 1000. The amendments are effective for years beginning on or after April 1, 2023. The Hospital is currently assessing the impact of the amended standards.

3 COVID-19 pandemic response

On March 11, 2020, the World Health Organization characterized the outbreak of a strain of the novel coronavirus (COVID-19) as a pandemic, which has resulted in a series of public health and emergency measures that have been put into place to combat the spread of the virus.

March 31, 2023

(in thousands of dollars)

For the year ended March 31, 2023, the Hospital received funding for pandemic-related incremental operating expenditures and reduction in non-MOH revenue that amounted to \$37,675 (2022 – \$71,527). Additionally, the Hospital incurred COVID-19 related capital expenditures that amounted to \$30 (2022 – \$415). These amounts were recognized respectively as COVID-19 funding in the statement of operations and changes in net deficit and deferred contributions in the statement of financial position in accordance with the Ministry's COVID-19 Incremental Hospital Expenses Guidance document. As at March 31, 2023, \$2,937 (2022 – \$12,682) of the revenue and deferred capital contributions recognized was included in accounts receivable in the statement of financial position.

In addition to the funding received during the year, the Hospital received a combined \$7,642 (2022 - \$3,743) in temporary nursing retention incentive funding for eligible staff and temporary physician pay funding that has been offset against salaries and wages and employee benefits in the statement of operations and changes in net deficit, since the Hospital acted as an agent for the Ministry in respect of distributing the pay to staff and physicians.

4 Restricted cash and investments

	2023 \$	2022 \$
Restricted cash held for redevelopment (a) Restricted cash under administration (b) Restricted investments for future capital investment (c)	7,084 12,798 190,598	6,564 14,036 27,066
	210,480	47,666
Externally restricted cash Internally restricted investments	19,882 190,598	20,600 27,066
Less: Restricted cash – current	210,480 12,798	47,666 14,036
Restricted cash and investments – long-term	197,682	33,630

- a) Restricted cash held for redevelopment consists of funds received from the MOH, under the terms of the Development Accountability Agreement with the MOH related to the Hennick Bridgepoint Hospital (HBH) redevelopment project that are restricted in use. The unspent portion of these funds as at March 31, 2023 was \$7,084 (2022 \$6,564), which is held in a sinking fund trust account.
- b) Restricted cash under administration consist of cash held and administered by the Hospital on behalf of the clinical groups and cannot be used for Hospital operations.
- c) Restricted investments for future capital investment consists of internally restricted funds for the purpose of investing in capital and equipment.

Notes to Financial Statements March 31, 2023

(in thousands of dollars)

5 Accounts receivable

	2023 \$	2022 \$
Research grants MOH	13,819 11,136	10,746 21,960
Commodity tax receivable	5,682	5,910
Patient services	7,967	6,531
Other	13,585	16,047
	52,189	61,194

Patient accounts receivable are shown net of an allowance for potentially uncollectible amounts of 1,614 (2022 – 547). Other accounts receivable are shown net of an allowance for potentially uncollectible amounts of 684 (2022 - 1,500).

6 Redevelopment receivable

The following are amounts due from the MOH related to the following capital projects:

	2023 \$	2022 \$
Renew Sinai, Phase 2 Renew Sinai, Phase 3A (note 10(b))	3,620 108,556	3,620 71,821
Less: Current portion	112,176 92,189	75,441 -
Long-term portion	19,987	75,441

7 Capital and intangible assets

			2023
	Cost \$	Accumulated amortization \$	Net \$
Land	64,388	-	64,388
Artwork	4,101	-	4,101
Building	1,309,806	587,006	722,800
Equipment	470,290	352,931	117,359
Equipment under capital lease	310	139	171
Software	5,813	5,389	424
Customer relationships	8,922	892	8,030
Lease agreement	8,328	2,221	6,107
Construction-in-progress (note 10(b))	478,337	-	478,337
	2,350,295	948,578	1,401,717

Notes to Financial Statements

March 31, 2023

(in thousands of dollars)

			2022
	Cost \$	Accumulated amortization \$	Net \$
Land	64,388	-	64,388
Artwork	4,101	-	4,101
Building	1,300,133	543,934	756,199
Equipment	455,425	342,543	112,882
Equipment under capital lease	310	200	110
Software	6,001	5,303	698
Customer relationships	8,922	446	8,476
Lease agreement	8,328	1,111	7,217
Construction-in-progress (note 10(b))	406,793	-	406,793
	2,254,401	893,537	1,360,864

Construction-in-progress reflects expenditures on assets not yet in use including Renew Sinai Phase 3A redevelopment and expansion project.

8 Long-term debt

	2023 \$	2022 \$
Series A senior unsecured debentures (c) Series B senior unsecured debentures (d)	198,405 199.825	198,380 199,825
Capital loan (b)	22,492	23,506
Capital equipment financing	3,127	4,071
Fair value adjustment in respect of interest rate swap agreements (e)	(561)	390
	423,288	426,172
Less: Current portion of long-term debt	2,139	2,047
Long-term portion	421,149	424,125

a) The Hospital has the following operating credit facilities available to draw upon:

i) An unsecured revolving term credit facility of \$36,500, available by way of advances at the bank's prime lending rate less 0.85% and bankers' acceptances fee. As at March 31, 2023 and 2022, no funds have been drawn on this term credit facility. The facility expired on April 15, 2023 and was renewed subsequent to year-end.

ii) An unsecured revolving credit facility of \$10,000, available by way of advances at the bank's prime lending rate and bankers' acceptances fee. As at March 31, 2023 and 2022, no funds have been drawn on this revolving credit facility.

- b) The Hospital has the following term facilities for capital available to draw upon:
 - i) An unsecured revolving term facility of \$10,000, available by way of advances at the bank's prime lending rate less 0.85% and bankers' acceptance fee, of which \$nil was drawn as at March 31, 2023 (2022 \$nil). The facility expired on April 15, 2023 and was renewed subsequent to year-end.
 - ii) An unsecured non-revolving term facility of \$30,000, maturing on December 1, 2039, with a fixed base rate of 3.05% plus a floating rate credit spread of 0.50% (2022 0.45%), of which \$22,492 (2022 \$23,506) was drawn as at March 31, 2023.
- c) On June 9, 2016, the Hospital issued \$200,000 of 3.527% Series A senior unsecured debentures at par value with a maturity date of June 9, 2056. Interest is payable semi-annually on June 9 and December 9, with the principal to be repaid on June 9, 2056. During the year, interest paid amounted to \$6,337 (2022 \$7,054). Interest expense recorded in the statement of operations and changes in net deficit amounted to \$3,739 (2022 \$4,388) and interest capitalized in capital and intangible assets amounted to \$2,598 (2022 \$2,666).
- d) On April 8, 2020, the Hospital issued \$200,000 of 3.209% Series B senior unsecured debentures at par value with a maturity date of April 8, 2060. Interest is payable semi-annually on April 8 and October 8 with the principal to be repaid on April 8, 2060. During the year, interest paid amounted to \$6,418 (2022 \$6,418). Interest expense recorded in the statement of operations and changes in net deficit amounted to \$6,418 (2022 \$6,418) and interest prepaid in prepaid deposits and sundry assets amounted to \$nil (2022 \$6,418).
- e) The Hospital has an interest rate swap contract relating to its unsecured non-revolving facility (8(b)(ii)), which is recorded at fair value. The fair value of the interest rate swap is based on current pricing for the same notional interest rate swap (Level 2 of the fair value hierarchy). The swap has a notional principal amount of \$30,000 maturing on December 1, 2039. During the year, an unrealized gain of \$951 (2022 gain of \$1,578) was recorded in the statement of remeasurement gains (losses). As at March 31, 2023, the swap was in a net favourable position and an asset of \$561 (2022 liability of \$390) was recorded on the statement of financial position.

Principal due within each of the next five years and thereafter on the long-term debt as at March 31, 2023 is as follows:

	\$
2024 2025 2026 2027 2028 Thereafter	2,139 2,115 2,106 1,145 1,180 415,164
	423,849

Notes to Financial Statements

March 31, 2023

(in thousands of dollars)

9 Other long-term liabilities

	2023 \$	2022 \$
Long-term accrued sick days Construction holdbacks Net obligation in government business enterprises (note 13) HIROC legal defense liability (note 15(c))	6,432 10,082 4,158 4,861	6,103 8,710 5,467 5,080
Asset retirement obligation (note 2)	1,549	
	27,082	25,360
10 Long-term redevelopment obligation		
	2023 \$	2022 \$
HBH long-term redevelopment obligation, due on February 28, 2043, monthly payments of \$2,112 including principal and interest at		
7.46%	320,084	329,181
Renew Sinai long-term redevelopment obligation	126,251	81,891
	446,335	411,072
Less: Current portion	135,813	9,097
Long-term portion	310,522	401,975

a) HBH Redevelopment Project

In July 2009, the MOH provided approval for HBH to enter into a project agreement with the successful bidder for the construction of HBH's Capital Redevelopment Project as a Design, Build, Finance and Maintain Alternative Financing and Procurement Project. The project agreement includes a 30-year facility maintenance period. The redeveloped HBH is purpose-built to serve those in need of rehabilitation services and those living with complex chronic disease.

The long-term redevelopment obligation relates to future capital payments associated with the Project Agreement. The Hospital has an agreement with the MOH to fund 100% of the long-term redevelopment obligation on an annual basis.

b) Renew Sinai Redevelopment Project

The Hospital has undertaken a major multi-year capital redevelopment project (Renew Sinai) to expand and modernize multiple care environments within Mount Sinai Hospital (MSH). Renew Sinai involves the expansion and modernization of the emergency department surgical suites, intensive care unit, key ambulatory patient areas and a new inpatient unit.

March 31, 2023

(in thousands of dollars)

In June 2017, the Hospital entered into a project agreement for the build and finance of the Renew Sinai Phase 3A redevelopment project. As part of the project funding agreement, the Ministry has committed to fund a portion of the capital and financing cost of the site. Accordingly, the Hospital has recorded a long-term receivable from the Ministry for its share (note 6). The local share of the costs of Renew Sinai Phase 3A will be funded by contributions from Sinai Health System Foundation and the Hospital, through internally generated funds and debenture financing (note 8(c)).

In the fiscal year ended March 31, 2023, work completed for building construction and financing costs totalled \$48,137 (2022 - \$37,241), for which the Hospital has recorded a corresponding redevelopment obligation of \$126,251 (2022 - \$81,891). An amount of \$258,642 (2022 - \$258,642) has been received from the MOH in prior years representing a portion of its funding share in accordance with the funding agreement. The Hospital has recognized as receivable amounts owing from the MOH for construction and ancillary costs for Phase 3A in the amount of \$108,556 (2022 - \$71,821) (note 6). A corresponding amount of \$366,858 (2022 - \$328,035) has been recorded in deferred capital contributions.

Payment due within each of the next five years and thereafter on the long-term redevelopment obligation is as follows:

	\$
2024 2025 2026 2027 2028 Thereafter	135,813 10,051 10,565 11,106 11,674 267,126
	446,335

11 Employee future benefits

Pension plan

Substantially all employees are eligible to be members of HOOPP, which is a multi-employer defined benefit pension plan. Plan members will receive benefits based on length of service and on the average of annualized earnings during the five consecutive years prior to retirement, termination or death that provide the highest earnings.

The most recent actuarial valuation of the Plan as at December 31, 2022 indicates the Plan is 117% funded. During the year, the Hospital contributed 31,316 (2022 - 31,366) to the Plan on behalf of employees.

Other post-employment benefits

The Hospital provides extended healthcare, dental and life benefits to certain of its employees and extends this coverage to the post-retirement period. In addition, a Supplemental Executive Retirement Plan (SERP) is available for a limited number of executive members. The related benefit liabilities were determined by actuarial valuation studies. The date of the last actuarial valuation for post-employment benefits and SERP was March 31,2022.

The employee future benefits as at March 31 include the following components:

			2023	2022
	SERP \$	Post- employment benefits \$	Total \$	Total \$
Accrued benefit obligation Unamortized actuarial gains (losses)	6,785 (297)	17,892 9,250	24,677 8,953	26,930 6,891
Employee future benefits liability Less: Current portion included in accounts payable and accrued liabilities	6,488 491	27,142 1,178	33,630 1,669	33,821 1,665
Long-term portion	5,997	25,964	31,961	32,156

The movement in the employee future benefits liability during the year is as follows:

			2023	2022
	SERP \$	Post- employment benefits \$	Total \$	Total \$
Employee future benefits liability – April 1, 2022	6,630	27,191	33,821	33,449
Current service cost Interest cost Amortization of actuarial gains (losses)	- 252 97	816 752 (420)	816 1,004 (323)	982 965 (45)
Pension and post-employment benefits expense	349	1,148	1,497	1,902
Benefits paid	(491)	(1,197)	(1,688)	(1,530)
Employee future benefits liability – March 31, 2023	6,488	27,142	33,630	33,821

The significant actuarial assumptions adopted in measuring the Hospital's accrued benefit obligations are as follows:

		2023		2022
	SERP %	Post- employment benefits %	SERP %	Post- employment benefits %
Discount rate Expected benefit cost trend in health care* Expected benefit cost trend in dental care	4.50 - -	4.50 - 4.60 5.70 3.00	3.00 - -	3.20 – 3.70 5.70 3.00

The average remaining service period of active employees is 13 to 16 years.

*The rate is presumed to decline by 0.25 percentage points per annum to an ultimate rate of 4.5%.

12 Deferred contributions

					2023	2022
	Capital funds \$	Designated fund \$	Research funds \$	Other operating \$	Total \$	Total \$
Balance – Beginning of year Additions to contributions Amortization/recognition	787,330 53,738 (27,056)	18,778 8,862 (5,751)	83,947 70,663 (67,967)	197 - -	890,252 133,263 (100,774)	842,795 169,953 (122,496)
Balance – End of year Less: Current portion	814,012 -	21,889 21,889	86,643 86,643	197 -	922,741 108,532	890,252 102,725
Long-term portion	814,012	-	-	197	814,209	787,527

Included in deferred capital contributions is \$10,642 (2022 – \$4,708) of unspent contributions received for specific purposes. The remaining portion of deferred capital contributions represents the unamortized amount of contributions, which has been used for the purchase of capital and intangible assets.

Notes to Financial Statements

March 31, 2023

(in thousands of dollars)

13 Related entities

Amounts due from and due to related entities are summarized as follows:

		2023		2022
Related entity	Due from \$	Due to \$	Due from \$	Due to \$
Hennick Bridgepoint Health The Centre for Phenogenomics Sinai Health System Foundation Mount Sinai Fertility Corporation Mount Sinai Services Inc. 2234998 Ontario Inc. Hennick Bridgepoint Foundation	768 961 10,576 10,264 965 49 358	169 376 - - - - -	790 1,165 10,176 11,905 2,045 50 14	182 901 - - - - -
Total Less: Long-term portion Sinai Health System	23,941	545	26,145	1,083
Foundation Mount Sinai Fertility Corporation	4,596 3,871	-	4,621 4,644	-
Total current portion	15,474	545	16,880	1,083

Hennick Bridgepoint Health (Health)

Bridgepoint Health is the legal name of Hennick Bridgepoint Health. Health is a non-share capital corporation incorporated pursuant to the laws of Canada. Health continued under the Canada Not-for-profit Corporations Act and is a registered charity and public foundation under the Income Tax Act (Canada). Health generates ancillary revenue to support the activities of the Hospital. Health is controlled by the Hospital given the members of Health are the elected Directors of the Hospital.

The Hospital provides space, banking and administrative services to Health. The Hospital makes payments and receives funds on behalf of Health and settles the outstanding balances at regular intervals throughout the year. No financing charges are levied on these interim balances. During the year, Health granted \$700 (2022 – \$700) in capital grants to the Hospital. The Hospital has credit facilities arranged related to its HBH capital redevelopment project. Health has provided a guarantee to the Hospital's credit facilities for its capital redevelopment project. As at March 31, 2023, there were no significant restrictions on the resources of Health and the accounting policies followed by Health substantially conform with those of the Hospital.

As at March 31, 2023, Health owed the Hospital \$768 (2022 - \$790), which was included in due from related entities and the Hospital owed Health \$169 (2022 - \$182), which was included in due to related entities. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related entities.

A financial summary of this non-consolidated entity as at March 31 is as follows:

	2023 \$	2022 \$
Financial position Total assets Total liabilities	8,012 778	7,723 872
Net assets	7,234	6,851
Results of operations Total revenue Total expenses	1,441 1,058	1,278 1,051
Excess of revenue over expenses	383	227

There were cash inflows of 425 (2022 - 330) from operating activities, cash outflows of 1 (2022 - 33) from capital activities and 1 (2022 - 31) from financing activities.

The Sinai Trust (Trust)

The Trust, of which the Hospital and Sinai Health System Foundation were beneficiaries, was a for-profit entity, established to develop commercial opportunities. The Trust had a December 31 year-end. Sinai Trustee Corporation, a non-share capital corporation incorporated pursuant to the laws of Canada, served as the trustee of the Trust. The Trust was controlled by the Hospital, as the Hospital Board of Directors was entitled to appoint trustees pursuant to the Trust.

On April 30, 2021, the Trust elected to distribute its net assets to the Hospital, as a beneficiary, and wind up its operations. The net assets were recorded at their book values adjusted for differences in accounting policies. A summary of the net assets received is as follows:

	\$
Investment in Mount Sinai Services Inc.	312
Investment in 2234998 Ontario Inc. Other assets Total liabilities	- 202 (196)
Net assets	318

For the year ended March 31, 2022, a gain on distribution from the Trust of \$67, representing the difference between the carrying value of the investment in the Trust and the net assets received, was recorded in other revenue and recoveries in the statement of operations and changes in net deficit.

The Centre for Phenogenomics (TCP)

TCP is an unincorporated joint venture between the Hospital and the Hospital for Sick Children, comprising a 120,000 square foot state-of-the-art mouse research facility. TCP is jointly controlled by the Hospital given its 50% interest in TCP. TCP entered into a lease with the Hospital in 2007 to rent space in the research building for a term of 30 years at a basic rent of \$10 per annum.

As at March 31, 2023, the Hospital had a net receivable due from TCP of \$585 (2022 - \$264).

A financial summary of this non-consolidated entity as at March 31 is as follows:

	2023 \$	2022 \$
Financial position		
Total assets Total liabilities	2,082 2,082	1,560 1,560
Net assets		-
Results of operations		
Total revenue Total expenses	9,558 9,558	9,181 9,181
Excess of revenue over expenses		-

Sinai Health System Foundation (SHSF)

SHSF is a non-share capital corporation incorporated pursuant to the laws of the Province of Ontario. SHSF is a charitable organization (public foundation) registered under the Income Tax Act (Canada). SHSF supports the Hospital in its charitable mission and provides donations to the Hospital for capital, clinical programs and research activities of Lunenfeld-Tanenbaum Research Institute (LTRI), a division of the Hospital. SHSF is significantly influenced by the Hospital given they have a limited number of common directors.

During the current year, the Hospital received 34,809 (2022 - \$25,398) in cash from SHSF. SHSF has contributed funding for a portion of the current year's bank interest expense in the amount of 82 (2022 - \$31).

As at March 31, 2023, the total net receivable from SHSF is \$10,576 (2022 – \$10,176), of which an estimated amount of \$5,980 (2022 – \$5,555) will be received within one year and is included in due from related entities. The remaining balance of \$4,596 (2022 – \$4,621) is accordingly classified as a long-term portion of due from related entities.

March 31, 2023

(in thousands of dollars)

The Sinai Trust 2017 (Trust 2017)

Trust 2017, of which the Hospital and SHSF were beneficiaries, was a for-profit entity established to develop commercial opportunities. Trust 2017 had a December 31 year-end. Sinai Trustee Corporation, a non-share capital corporation incorporated pursuant to the laws of Canada, served as the trustee of Trust 2017. Trust 2017 was controlled by SHSF, as SHSF was entitled to appoint trustees pursuant to the Trust Deed establishing Trust 2017.

On April 30, 2021, Trust 2017 elected to distribute its net liabilities to the Hospital, as a beneficiary, and wind up its operations. The net liabilities were recorded at their book values adjusted for differences in accounting policies. A summary of the net liabilities received is as follows:

	\$
Cash Other assets Obligation in Mount Sinai Fertility Corporation Other liabilities	3,883 2,997 (8,333) (446)
Net liabilities	(1,899)

For the year ended March 31, 2022, a loss on distribution from Trust 2017 of \$1,899 was recorded in other revenue and recoveries in the statement of operations and changes in net deficit.

Mount Sinai Fertility Corporation (MSF)

MSF is a for-profit corporation that provides a range of fertility services primarily through private contracts and, to a smaller extent, ministry supported programs.

For the year ended March 31, 2023, the Hospital recorded equity income from MSF of \$1,098 (2022 – \$2,294) in the statement of operations and changes in net deficit. As at March 31, MSF owes the Hospital the following amounts:

	2023 \$	2022 \$
Promissory notes Other receivables	7,740 2,523	7,740 4,165
Less: Current portion	10,263 6,392	11,905 7,261
Long-term portion	3,871	4,644

The promissory note is in the amount of \$7,740, bearing interest at prime plus 1% accruing since issuance and paid annually on the last day each year beginning March 31, 2020. Principal is payable in ten equal annual instalments of \$774 beginning March 31, 2020.

A financial summary of this non-consolidated entity as at March 31, 2023 is as follows:

	2023 \$	2022 \$
Financial position		
Total assets Total liabilities	7,298 12,245	7,341 13,381
Net liabilities	(4,947)	(6,040)
Results of operations		
Total revenue Total expenses	18,363 17,265	17,066 14,772
Excess of revenue over expenses	1,098	2,294

Mount Sinai Services Inc. (MSS)

MSS is a for-profit corporation that provides a range of laboratory services primarily through private contracts.

For the period ended March 31, 2022, the Hospital recorded equity income from MSS of \$88 (2022 - 246) in the statement of operations and changes in net deficit. As at March 31, 2023, the Hospital had a net receivable due from MSS of \$965 (2022 - 22,045).

A financial summary of this non-consolidated entity as at March 31, 2023 is as follows:

	2023 \$	2022 \$
Financial position		
Total assets	2,252	3,405
Total liabilities	1,606	2,847
Net assets	646	558
Results of operations	0.404	0.040
Total revenue	3,134	3,318
Total expenses	3,046	3,072
Excess of revenue over expenses	88	246

2234998 Ontario Inc.

2234998 Ontario Inc. is a for-profit corporation that operates a rehabilitation and wellness clinic.

For the period ended March 31, 2022, the Hospital recorded equity loss from 2234998 Ontario Inc. of \$3 (2022 – income of \$246) in the statement of operations and changes in net deficit. As at March 31, 2023, the Hospital had a net receivable due from 2234998 Ontario Inc. of \$49 (2022 – \$50).

A financial summary of this non-consolidated entity as at March 31, 2023 is as follows:

	2023 \$	2022 \$
Financial position		
Total assets	803	3,405
Total liabilities	773	2,847
Net assets	30	558
Results of operations		
Total revenue	1,843	3,318
Total expenses	1,846	3,072
(Deficiency) excess of revenue over expenses	(3)	246

Hennick Bridgepoint Foundation (BF)

Bridgepoint Foundation is the legal name of the Hennick Bridgepoint Foundation. BF is a non-share capital corporation incorporated pursuant to the laws of the Province of Ontario. BF is a registered charity (public foundation) under the Income Tax Act (Canada). BF supports the Hospital in its charitable mission and grants funds to the Hospital as approved by the Board of Directors of BF. BF is significantly influenced by the Hospital given they have a limited number of common directors.

During the year, BF provided operating grants in the amount of \$20 (2022 – \$15) and capital grants in the amount of \$280 (2022 – \$401).

Circle of Care (CoC)

CoC is a community-based not-for-profit agency whose objectives include providing home care services to individuals across Metropolitan Toronto that is affiliated with the Hospital. CoC is a registered charity (charitable organization) under the Income Tax Act (Canada). CoC is a separate corporation with its own Board of Directors. CoC is significantly influenced by the Hospital given the Hospital's Board of Directors is responsible for appointing 50% of the CoC Board of Directors.

There were no significant transactions between the Hospital and CoC for the year ended March 31, 2023.

14 Statement of cash flows

a) The net change in non-cash working capital balance relating to operations consists of the following:

		2023 \$	2022 \$
	Accounts receivable Inventories Prepaid deposits and sundry assets Accounts payable and accrued liabilities Administered funds	8,754 (1,671) 971 14,977 (1,238)	2,466 196 355 70,616 (1,815)
		21,793	71,818
b)	Non-cash transactions		
		2023 \$	2022 \$
	Financing of costs incurred on Renew Sinai Phase 3A redevelopment project Due from MOH related to Renew Sinai Phase 3A redevelopment	44,360	37,251
	project recorded as deferred capital contributions Net obligation in government business enterprises acquired on	36,735	54,674
	distribution from Trusts Promissory note payable retired on distribution from Trusts	-	8,021 2,350

15 Commitments and contingencies

- a) From time to time, the Hospital is named in lawsuits related to its activities. These claims are at various stages and therefore it is not possible to determine the merits of these claims or to estimate the possible financial liability, if any, to the Hospital. Accordingly, no material provisions have been made for loss in these financial statements.
- b) Future operating commitments related to future lifecycle costs, leases and contracts for facility operating and maintenance as at March 31, 2023 are as follows:

	\$
2024 2025 2026 2027 2028 Thereafter	14,496 14,092 13,657 12,776 12,718 127,684
	195,423

c) The Hospital is a member of Healthcare Insurance Reciprocal of Canada (HIROC) and therefore has an economic interest in HIROC. HIROC is a pooling of the public liability insurance risks of its members, which are Canadian not-for-profit healthcare organizations. All members of HIROC pay annual premiums, which are actuarially determined. All members are subject to assessment for losses, if any, experienced by the pool for the years in which they were members. No assessment has been made for the year ended March 31, 2023.

Since its inception in 1987, HIROC has accumulated an unappropriated surplus, which is the total of premiums paid by all subscribers plus investment income, less the obligation for claims reserves and expenses and operating expenses.

The Hospital entered into an agreement with HIROC, dated January 1, 2012, whereby HIROC continues to provide indemnity insurance to the Hospital; however, the cost of investigating and defending any litigation claims, previously included in the insurance premium, will be borne by the Hospital. Costs associated with claims arising prior to January 1, 2012 will be borne by HIROC. Projected costs of defending claims that arise subsequent to January 1, 2012 are based on claims defence costs incurred by HIROC in the past.

Under the agreement, the Hospital provides deposits to HIROC Management Limited (HML), which acts as an agent to pay legal expenses on behalf of the Hospital. For the year ended March 31, 2023, the Hospital has recorded legal expenses of \$1,223 (2022 – \$1,157) based on the assessment of the actuary engaged by HML, which have been included in the statement of operations and changes in net deficit. As at March 31, 2023, the deposit balance was \$8,501 (2022 – \$7,697), of which \$7,524 (2022 – \$6,704) is not expected to be used within one year and is therefore disclosed as a long-term asset, and the total liability was estimated to be \$5,453 (2022 – \$5,688), of which \$4,476 (2022 – \$4,695) is not expected to be paid within one year and is therefore disclosed as part of other long-term liabilities (note 9).

d) The Hospital has an agreement with Plexxus, whose primary responsibility is to provide supply chain services in the areas of strategic sourcing, logistics, buying and certain information technology services. The objective is to provide these services at a lower cost as compared to the members' costs prior to entering into the agreement. The term of the agreement is to March 31, 2021, but it includes an evergreen clause with existing terms and conditions until formal notice to terminate is provided or the agreement is renegotiated. Based on the agreement, Plexxus has the right to charge membership fees to its members. A process is established in the agreement for Plexxus to obtain the approval of the members to charge additional fees. If any member fails to pay their membership fees to Plexxus throughout the period covered by the agreement, the Hospital and the other members are responsible for lending an amount to Plexxus, based on a sharing formula, to cover these deficiencies. As at March 31, 2023, no member was in default.

On April 1, 2023, Plexxus and Mohawk Medbuy (MMC) amalgamated and will continue under the Mohawk Medbuy name.

e) The Hospital has entered into various contracts for construction and purchase of capital equipment. The commitments outstanding as at March 31, 2023 are estimated to be \$27,852 (2022 – \$55,154).

f) In November 2022, the company engaged as the contractor for Renew Sinai filed a claim seeking schedule relief and monetary compensation. In June 2023, the Hospital and the contractor reached a non-binding settlement agreement under which the Hospital would pay the contractor a total of \$20,900. Of this amount, \$14,707 is to be recovered by the Hospital from the Ministry once the settlement is finalized. The Hospital has accrued the settlement amount and the recoverable Ministry share as at March 31, 2023.

16 Risk management

The Hospital is exposed to a variety of financial risks, including credit risk, liquidity risk and market risk. The Hospital has adopted an integrated risk management framework. The framework provides a consistent methodology to manage risks across the Hospital.

Credit risk

The Hospital's credit risk is primarily attributable to its accounts receivable. The amounts disclosed in the statement of financial position are net of an allowance for doubtful accounts, estimated by the management of the Hospital based on previous experience and its assessment of the current economic environment. The Hospital is exposed to credit risk in the event of non-payment by patients for non-insured services and services provided to non-resident patients. The risk is common to hospitals as they are required to provide care for patients regardless of their ability to pay for services provided.

As at March 31, 2023, the following accounts receivable were past due but not impaired:

	30 days \$	60 days \$	90 days \$	Over 90 days \$	Total \$
Patient services receivable	3,851	1,743	359	2,014	7,967

The credit risk on other financial assets such as cash and due from related entities is limited because the counterparties are chartered banks with high credit ratings assigned by national credit rating agencies and the Hospital is assured of collection from related parties.

Liquidity risk

Liquidity risk is the possible risk of not being able to meet financial obligations when due. The Hospital manages its liquidity risk by forecasting cash flows from operations and anticipating capital, investing and financing activities and maintaining credit facilities to ensure it has sufficient funds available to meet current and foreseeable financial requirements.

The table below is a maturity analysis of the Hospital's financial liabilities as at March 31, 2023:

	Up to 6 months \$	More than 6 months up to 1 year \$	More than 1 year up to 5 years \$	More than 5 years \$	Total \$
Accounts payable and accrued					
liabilities	160,027	89,999	-	-	250,026
Long-term debt	519	1,620	6,546	414,603	423,288
Interest on long-term debt Long-term redevelopment	7,076	7,068	56,258	413,018	483,420
obligation Interest on long-term	26,016	109,797	43,396	267,126	446,335
redevelopment obligation	7,953	7,834	58,000	113,108	186,895
	201,591	216,318	164,200	1,207,855	1,789,964

Market risk

The Hospital is exposed to market risk through the fluctuation of financial instrument fair values due to changes in market prices. Interest rate risk is the significant market risk, which arises from fluctuations in interest rates and the degree of volatility of those rates. The Hospital is exposed to interest rate risk on its long-term debt (note 8). The Hospital has mitigated this risk by way of an interest rate swap, which effectively fixes the interest rates of a portion of the long-term debt.

As at March 31, 2023, the Hospital's estimate of the exposure to interest rate risk and the effect on net assets is not material.

17 Comparative figures

Certain comparative figures have been reclassified to conform to the current year's financial statement presentation, including the purchase of capital and intangible assets from investing activities to capital activities in the statement of cash flows.